Latest Breaking News On - He menarini group - Page 1 : comparemela.com

The European Commission has approved the Menarini Group’s Orsedu (elacestrant) as a monotherapy for the treatment of postmenopausal women and men with breast cancer.

Elcin barker ergunGiuseppe curiglianoMenarini groupEuropean institute of oncologyEuropean commissionEuropean medicines agencyMedicinal productsHuman useBarker ergunEuropean instituteBio developmentsHe menarini groupBreast cancer